Aquestive Therapeutics Inc (AQST) is now in the Overvalued zone, suggesting that its current forward PS ratio of 13.90 is considered Overvalued compared with the five-year average of -4.64. The fair price of Aquestive Therapeutics Inc (AQST) is between 0.81 to 2.41 according to relative valuation method. Compared to the current price of 4.21 USD , Aquestive Therapeutics Inc By Overvalued By 74.48%.

Relative Value

Fair Zone

0.81-2.41

Current Price：4.21

74.48%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Aquestive Therapeutics Inc (AQST) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Aquestive Therapeutics Inc (AQST) has a current Price-to-Book (P/B) ratio of -190.98. Compared to its 3-year average P/B ratio of -21.61, the current P/B ratio is approximately 783.76% higher. Relative to its 5-year average P/B ratio of -13.31, the current P/B ratio is about 1335.23% higher. Aquestive Therapeutics Inc (AQST) has a Forward Free Cash Flow (FCF) yield of approximately -6.47%. Compared to its 3-year average FCF yield of -4.50%, the current FCF yield is approximately 44.01% lower. Relative to its 5-year average FCF yield of -19.72%, the current FCF yield is about -67.17% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for AQST competitors is 7.82, providing a benchmark for relative valuation. Aquestive Therapeutics Inc Corp (AQST.O) exhibits a P/S ratio of 13.90, which is 77.65% above the industry average. Given its robust revenue growth of -5.43%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of AQST increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of AQST in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is AQST currently overvalued or undervalued?

Aquestive Therapeutics Inc (AQST) is now in the Overvalued zone, suggesting that its current forward PS ratio of 13.90 is considered Overvalued compared with the five-year average of -4.64. The fair price of Aquestive Therapeutics Inc (AQST) is between 0.81 to 2.41 according to relative valuation method. Compared to the current price of 4.21 USD, Aquestive Therapeutics Inc is Overvalued By 74.48%.

What is Aquestive Therapeutics Inc (AQST) fair value?

AQST's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Aquestive Therapeutics Inc (AQST) is between 0.81 to 2.41 according to relative valuation method.

How does AQST's valuation metrics compare to the industry average?

The average P/S ratio for AQST's competitors is 7.82, providing a benchmark for relative valuation. Aquestive Therapeutics Inc Corp (AQST) exhibits a P/S ratio of 13.90, which is 77.65% above the industry average. Given its robust revenue growth of -5.43%, this premium appears unsustainable.

What is the current P/B ratio for Aquestive Therapeutics Inc (AQST) as of Mar 02 2026?

As of Mar 02 2026, Aquestive Therapeutics Inc (AQST) has a P/B ratio of -190.98. This indicates that the market values AQST at -190.98 times its book value.

What is the current FCF Yield for Aquestive Therapeutics Inc (AQST) as of Mar 02 2026?

As of Mar 02 2026, Aquestive Therapeutics Inc (AQST) has a FCF Yield of -6.47%. This means that for every dollar of Aquestive Therapeutics Inc's market capitalization, the company generates -6.47 cents in free cash flow.

What is the current Forward P/E ratio for Aquestive Therapeutics Inc (AQST) as of Mar 02 2026?

As of Mar 02 2026, Aquestive Therapeutics Inc (AQST) has a Forward P/E ratio of -9.94. This means the market is willing to pay $-9.94 for every dollar of Aquestive Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Aquestive Therapeutics Inc (AQST) as of Mar 02 2026?

As of Mar 02 2026, Aquestive Therapeutics Inc (AQST) has a Forward P/S ratio of 13.90. This means the market is valuing AQST at $13.90 for every dollar of expected revenue over the next 12 months.

AQST Valuation